Profile data is unavailable for this security.
About the company
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
- Revenue in USD (TTM)15.13m
- Net income in USD-44.05m
- Incorporated2017
- Employees64.00
- LocationJanux Therapeutics Inc10955 Vista Sorrento Parkway, Suite 200SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 751-4493
- Fax+1 (302) 655-5049
- Websitehttps://www.januxrx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novavax Inc | 987.67m | -294.33m | 2.18bn | 1.54k | -- | -- | -- | 2.21 | -2.76 | -2.76 | 7.41 | -2.70 | 0.5638 | 21.98 | 4.63 | 640,095.30 | -16.80 | -46.06 | -78.53 | -269.57 | 63.67 | -- | -29.80 | -75.94 | 1.03 | -18.79 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Vera Therapeutics Inc | 0.00 | -107.85m | 2.24bn | 72.00 | -- | 6.83 | -- | -- | -2.20 | -2.20 | 0.00 | 5.98 | 0.00 | -- | -- | 0.00 | -36.41 | -- | -39.42 | -- | -- | -- | -- | -- | -- | -- | 0.1329 | -- | -- | -- | -7.79 | -- | -- | -- |
Keros Therapeutics Inc | 271.00k | -168.05m | 2.29bn | 149.00 | -- | 5.23 | -- | 8,432.09 | -5.13 | -5.13 | 0.0082 | 11.64 | 0.0007 | -- | -- | 1,992.65 | -41.43 | -35.95 | -43.43 | -38.07 | -- | -- | -62,012.55 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
Arrowhead Pharmaceuticals Inc | 19.65m | -538.64m | 2.34bn | 525.00 | -- | 7.07 | -- | 119.08 | -4.65 | -4.65 | 0.1701 | 2.66 | 0.0234 | -- | -- | 37,424.76 | -65.18 | -20.02 | -73.62 | -24.65 | -- | -- | -2,785.85 | -61.79 | -- | -154.93 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
Janux Therapeutics Inc | 15.13m | -44.05m | 2.35bn | 64.00 | -- | 3.57 | -- | 155.25 | -0.9152 | -0.9152 | 0.3088 | 12.61 | 0.0293 | -- | -- | 236,359.40 | -8.53 | -- | -8.78 | -- | -- | -- | -291.17 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Agios Pharmaceuticals Inc | 31.31m | -364.93m | 2.35bn | 383.00 | -- | 3.56 | -- | 75.10 | -6.49 | -6.49 | 0.5568 | 11.61 | 0.0337 | 0.1687 | 10.41 | 81,738.91 | -39.28 | -29.54 | -41.94 | -31.88 | 89.33 | -- | -1,165.69 | -3,826.10 | 9.71 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
Azenta Inc | 658.62m | -156.38m | 2.36bn | 3.30k | -- | 1.22 | -- | 3.59 | -2.82 | -2.81 | 11.73 | 39.50 | 0.2443 | 3.08 | 3.49 | 188,176.30 | -5.80 | -0.5934 | -6.27 | -0.6725 | 39.78 | 43.08 | -23.74 | -2.17 | 4.21 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
Neumora Therapeutics Inc | 0.00 | -274.18m | 2.36bn | 108.00 | -- | 6.19 | -- | -- | -1.66 | -1.66 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -71.73 | -- | -76.67 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Immunitybio Inc | 1.31m | -597.65m | 2.39bn | 622.00 | -- | -- | -- | 1,826.54 | -0.9356 | -0.9356 | 0.0021 | -1.01 | 0.0036 | -- | 0.49 | 2,082.80 | -162.54 | -112.76 | -1,927.61 | -316.07 | -- | -- | -45,701.07 | -37,700.74 | 3.88 | -2.33 | 3.69 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
SpringWorks Therapeutics Inc | 86.19m | -301.06m | 2.42bn | 305.00 | -- | 4.35 | -- | 28.13 | -4.44 | -4.44 | 1.25 | 7.50 | 0.1519 | -- | -- | 282,577.10 | -53.07 | -36.97 | -57.99 | -39.49 | 95.27 | -- | -349.32 | -2,176.46 | 7.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
CG Oncology Inc | 650.00k | -75.84m | 2.46bn | 61.00 | -- | 4.42 | -- | 3,780.05 | -1.17 | -1.17 | 0.01 | 8.29 | -- | -- | -- | 10,655.74 | -- | -- | -- | -- | -- | -- | -9,870.92 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -100.44m | 2.46bn | 136.00 | -- | 2.67 | -- | -- | -2.24 | -2.24 | 0.00 | 16.10 | 0.00 | -- | -- | 0.00 | -17.07 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
ACADIA Pharmaceuticals Inc | 890.53m | 30.57m | 2.50bn | 630.00 | 83.28 | 4.85 | 59.60 | 2.81 | 0.1813 | 0.1813 | 5.38 | 3.12 | 1.14 | 1.83 | 9.60 | 1,491,682.00 | 3.93 | -27.50 | 5.93 | -32.73 | 91.72 | 95.62 | 3.43 | -38.35 | 1.95 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
Veracyte Inc | 399.58m | -54.04m | 2.52bn | 815.00 | -- | 2.23 | -- | 6.31 | -0.7444 | -0.7444 | 5.37 | 14.76 | 0.3336 | 8.11 | 8.62 | 490,281.00 | -4.51 | -6.33 | -4.77 | -6.69 | 68.73 | 67.10 | -13.52 | -20.99 | 4.17 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
Ideaya Biosciences Inc | 11.96m | -153.74m | 2.53bn | 124.00 | -- | 2.45 | -- | 211.70 | -2.18 | -2.18 | 0.1718 | 12.24 | 0.0159 | -- | 148.57 | 96,451.61 | -20.48 | -19.17 | -21.42 | -21.05 | -- | -- | -1,285.44 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 26 Jun 2024 | 9.17m | 17.68% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.55m | 14.56% |
BVF Partners LPas of 31 Mar 2024 | 2.92m | 5.63% |
Adage Capital Management LPas of 31 Mar 2024 | 2.78m | 5.35% |
Citadel Advisors LLCas of 31 Mar 2024 | 2.31m | 4.46% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.95m | 3.77% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.53m | 2.95% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.33m | 2.56% |
RTW Investments LPas of 31 Mar 2024 | 1.00m | 1.93% |
Cormorant Asset Management LPas of 31 Mar 2024 | 750.00k | 1.45% |